HBIO vs UTHR · rev $22.7M vs P/E 20, rev $1.56B
Harvard Bioscience Inc (HBIO) versus United Therapeutics Corporation (UTHR) — a side-by-side from cached financials, not a winner call.
Harvard Bioscience Inc (HBIO) is a medical instruments & supplies company listed on US.
United Therapeutics Corporation (UTHR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported HBIO revenue for 2026-06-30 was $22.7M. Net income was -$2.9M. Revenue was up 9.5% from 2026-03-31 to 2026-06-30. HBIO currently screens at market cap $20.3M.
Latest reported UTHR revenue for 2026-06-30 was $1.56B. Net income was $607.9M. UTHR currently screens at market cap $23.41B and trailing P/E 20.4.
HBIO currently screens at market cap $20.3M. UTHR currently screens at market cap $23.41B and trailing P/E 20.4.
Not investment advice. Open the HBIO and UTHR stock pages for the full models.
Not investment advice.